In ovarian cancer, it can target ORP4, which is associated with proliferative activity (Bensen et al., 2021); In breast cancer, it can decrease the expression of NFATc2 to inhibit tumor growth and metastasis (Ding et al., 2020). This evidence concerns the gene OSBP2 and ovarian carcinoma.